Meeting
2014 ASCO Annual Meeting
Relationship between tumor biomarkers (BM) and efficacy in TH3RESA, a phase 3 study of trastuzumab emtansine (T-DM1) versus treatment of physician’s choice (TPC) in HER2-positive advanced breast cancer (BC) previously treated with trastuzumab and lapatinib.
Authors
Sung-Bae Kim
Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea
Sung-Bae Kim , Hans Wildiers , Ian E. Krop , Abraham C.F. Leung , Caroline Trudeau , Ron Yu , Sanne de Haas , Antonio Gonzalez-Martin
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer - HER2/ER
Track
Breast Cancer
Sub Track
HER2+
Clinical Trial Registration Number
NCT01419197
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 605)
DOI
10.1200/jco.2014.32.15_suppl.605
Abstract #
605
Poster Bd #
69
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
Assessment of ESR1 and ERBB2 mutations in estrogen receptor positive (ER+) metastatic breast cancers (MBC).
First Author: Gargi D. Basu
Poster
2016 ASCO Annual Meeting
Impact of somatic PIK3CA and ERBB family mutations on pathological complete reponse (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapies.
First Author: Sinead Toomey
Poster
2015 ASCO Annual Meeting
Phase I study of LJM716, BYL719, and trastuzumab in patients (pts) with HER2-amplified (HER2+) metastatic breast cancer (MBC).
First Author: Payal Deepak Shah
Poster
2019 ASCO Annual Meeting
A phase III study comparing trastuzumab emtansine with trastuzumab, pertuzumab, and docetaxel in elderly patients with advanced stage HER2-positive breast cancer: (JCOG1607 HERB TEA study).
First Author: Akihiko Shimomura